Animal health industry is evolving from being a small part of pharma companies with little interest to an important and distinct part of the healthcare sector. (J.P Morgan 2016)
From its inception in 2011, Vetbiobank has taken advantages of relatively low R&D cost to successfully develop innovative and superior cell therapy products and quickly evaluate the drugs in the intended species.
This regenerative therapy is based upon collecting neonatal stem cells from the placenta or cord blood of healthy validated donors that can be cryopreserved indefinitely and are administered, to non-related allogeneic individuals.
Today, Vetbiobank provides vets with this innovative neonatal stem cell based therapy addressing multiple chronic inflammatory diseases markets and first osteoarthritis market (concerns 20% of dogs and 50% of athlete horses - €440m in Europe and USA).
A unique answer to a strong and proven demand for a single injection providing long term remission of arthrosis signs and improving mobility.
Vetbiobank products are validated under stringent laboratory conditions and have now been used to treat successfully over 700 horses and 200 dogs with an owner satisfaction of >80%.
Future industrial, regulatory and commercial development of Vetbiobank relies on its key success factors, on the newly signed partnership with one of the top 10 animal health pharma company plus an anticipated fund raising of 3.2m€.